Hi Bill, I've looked extensively at the company and I really can't come up with a reason why it's undervalued, maybe some legacy investors wanted to get out. Given the rate of financial improvement, I don't think the undervaluation will last.

Thanks Susan, appreciated.

Well, that really depends on pricing and as far as I'm aware, no other treatment is available for HSCT-TMA, they got orphan drug designation

Appreciated Kenny, my pleasure. It's a very interesting company that is really undervalued IMHO.

My pleasure Ori, the market cap is waaaay too low, IMHO. 

Thanks for the comments people, appreciated, I also see a favorable risk/reward ratio.

Thanks, appreciated Kurt. I agree, the platform has already proven itself by generating many useful compounds which are now being commercialized by five different subsidiaries, some of which already selling commercial products and some of them worth more than Evogene itself.

Yes, thanks, this would help many people. 

Thanks people, it seems a pretty good opportunity here, IMHO.